These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20685748)

  • 1. Cardiovascular events in patients with COPD: TORCH study results.
    Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Crim C; Willits LR; Yates JC; Vestbo J;
    Thorax; 2010 Aug; 65(8):719-25. PubMed ID: 20685748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
    N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
    Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD.
    Dransfield MT; Cockcroft JR; Townsend RR; Coxson HO; Sharma SS; Rubin DB; Emmett AH; Cicale MJ; Crater GD; Martinez FJ
    Respir Med; 2011 Sep; 105(9):1322-30. PubMed ID: 21696934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP
    Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
    Jenkins CR; Jones PW; Calverley PM; Celli B; Anderson JA; Ferguson GT; Yates JC; Willits LR; Vestbo J
    Respir Res; 2009 Jun; 10(1):59. PubMed ID: 19566934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
    Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.
    Malone R; LaForce C; Nimmagadda S; Schoaf L; House K; Ellsworth A; Dorinsky P
    Ann Allergy Asthma Immunol; 2005 Jul; 95(1):66-71. PubMed ID: 16095144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C; Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Willits LR; Yates JC; Vestbo J
    Eur Respir J; 2009 Sep; 34(3):641-7. PubMed ID: 19443528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y
    Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
    Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of salmeterol in the maintenance treatment of asthma.
    Nathan RA; Seltzer JM; Kemp JP; Chervinsky P; Alexander WJ; Liddle R; Mills R
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):243-8. PubMed ID: 7552926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.